Recurrent Mantle Cell Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
C
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
Active, not recruiting
Has Results
  • Recurrent Grade 1 Follicular Lymphoma
  • +4 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +6 more
  • Duarte, California
    City of Hope Comprehensive Cancer Center
2021-11-22
Nov 22, 2021
J
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Recruiting
  • Indolent B-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2021-12-17
Dec 17, 2021
V
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Active, not recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Birmingham, Alabama
  • +4 more
2021-11-09
Nov 9, 2021
M
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Low Dose Radiation Therapy
  • Houston, Texas
    M D Anderson Cancer Center
2021-10-01
Oct 1, 2021
N
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma - 2021
Completed
Has Results
  • Recurrent Follicular Lymphoma
  • +10 more
  • Denver, Colorado
  • +10 more
2021-09-04
Sep 4, 2021
K
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +8 more
  • PI3K inhibitor BKM120
  • +3 more
  • Atlanta, Georgia
  • +1 more
2021-09-29
Sep 29, 2021
M
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +9 more
  • Cryosurgery
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2021-09-03
Sep 3, 2021
S
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia
  • +67 more
  • Fludarabine phosphate
  • +8 more
  • Philadelphia, Pennsylvania
    Thomas Jefferson University
2021-08-31
Aug 31, 2021
N
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas - 2018
Terminated
Has Results
  • Adult Grade III Lymphomatoid Granulomatosis
  • +116 more
  • brentuximab vedotin
  • +2 more
  • Chicago, Illinois
  • +2 more
2021-08-30
Aug 30, 2021
J
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Recruiting
  • CD19 Positive
  • +13 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
2021-08-10
Aug 10, 2021
U
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma - 2020
Terminated
Has Results
  • Ann Arbor Stage I Mantle Cell Lymphoma
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-07-16
Jul 16, 2021
N
Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL) - 2021
Terminated
  • Recurrent Anaplastic Large Cell Lymphoma
  • +7 more
  • Los Angeles, California
  • +18 more
2021-07-20
Jul 20, 2021
C
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
Recruiting
  • B-Cell Prolymphocytic Leukemia
  • +17 more
  • Buffalo, New York
  • +1 more
2021-07-04
Jul 4, 2021
C
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Acalabrutinib
  • CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
  • Duarte, California
    City of Hope Comprehensive Cancer Center
2021-06-15
Jun 15, 2021
C
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +4 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +8 more
  • Duarte, California
    City of Hope Medical Center
2021-06-12
Jun 12, 2021
M
CD19-Specific T Cells Post AlloSCT - 2021
Terminated
  • B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
  • +16 more
  • Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-05-28
May 28, 2021
D
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Recruiting
  • Grade 3a Follicular Lymphoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Atlanta, Georgia
  • +1 more
2021-05-13
May 13, 2021
B
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma - 2015
Completed
Has Results
  • Adult Grade III Lymphomatoid Granulomatosis
  • +88 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
2021-04-14
Apr 14, 2021
M
Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial
Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Biospecimen Collection
  • Follow-Up
  • Houston, Texas
    M D Anderson Cancer Center
2021-04-30
Apr 30, 2021
R
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors - 2018
Completed
Has Results
  • Adult Acute Lymphoblastic Leukemia in Remission
  • +58 more
  • Buffalo, New York
    Roswell Park Cancer Institute
2021-03-23
Mar 23, 2021
F
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies - 2018
Terminated
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +32 more
  • indium In 111 anti-CD45 monoclonal antibody BC8
  • +2 more
  • Seattle, Washington
    Fred Hutchinson Cancer Research Center/University of Washington
2021-03-07
Mar 7, 2021
M
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-02-21
Feb 21, 2021
K
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
2021-02-20
Feb 20, 2021
F
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Completed
  • Hematopoietic/Lymphoid Cancer
  • +135 more
  • beclomethasone dipropionate
  • +4 more
  • Hackensack, New Jersey
  • +1 more
2021-02-01
Feb 1, 2021
N
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma - 2015
Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +35 more
  • Akt inhibitor MK2206
  • laboratory biomarker analysis
  • Houston, Texas
    M D Anderson Cancer Center
2020-10-14
Oct 14, 2020